Benzinga - Feed Your Mind.

Market Overview

GlaxoSmithKline in Talks with Human Genome Sciences -Sources

Charles Gross, Benzinga Staff Writer

July 15, 2012 9:12 PM

Tickers: GSK, HGSI

GlaxoSmithKline (NYSE: GSK) is reportedly in discussions this weekend with Human Genome Sciences (NASDAQ: HGSI) to increase its previous offer, according to Reuters.

Human Genome had previously rejected GSK's $13/share bid. There was heavy volume in the October 16 HGSI call on Friday just before the close. HGSI closed at $13.58 on Friday.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted in: News, Options, Rumors, M&A, Pre-Market Outlook, Markets

Around the Web, We're Loving...

For the Fastest Financial Updates, Click Here!

Lululemon's fake CEO job listing draws 160 resumes

Gen. Hayden to Newsmax: Spying Programs 'Keep You Safe, Keep You Free'

Adobe Systems Q2 Cloud Progress Under Microscope

What Should You Know About AMZN?

Most Popular

Apple Could Make 'Hundreds of Millions' in L.A. School Deal (AAPL)

If Xbox One Flops, Will Microsoft Remove the DRM and Daily Connection Requirement? (MSFT)

Men's Warehouse Board Kicks Founder and Brand Image George Zimmer to the Curb (MW)

Natura Pet Issues Voluntary Recall of Specialized Dry Pet Foods Due to Possible Health Risk

Interesting Insider Trade Ahead of Micron Earnings (MU)

Up 500 Percent This Year, Investors Are Still Overlooking This Small Cap Stock

Related Articles (HGSI + GSK)

AstraZeneca to Acquire Pearl Therapeutics to Gain Foothold into Lucrative Market (AZN, GSK, NVS)

FDA Approves Two Skin Cancer Treatments for GlaxoSmithKline

Glaxo, Genmab Offer Positive Top-Line Results from Pivotal Study of ARZERRA, Chlorabucil Combo

UPDATE: Deutsche Bank Upgrades GlaxoSmithKline to a Buy on Risk/Reward Move to Positive

Benzinga's Top Upgrades

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

View the discussion thread.

Partner Network

Posts by Charles Gross

Benzinga Professional

08:06 PM Ebix, Goldman Sachs Affiliate to Terminate Merger Agreement
08:05 PM 'Hemlock Grove' to Return for Second Season on Netflix
08:03 PM Repros Therapeutics Prices 3.75M Share Offering at $19.00/Share
08:01 PM Kayne Anderson Increases Distribution to $0.58/Share for Q2 2013
08:01 PM CVB Financial Increases Q2 2013 Dividend 18%
07:08 PM Finisar Beats Estimates; Provides Q1 Guidance Above Consensus (FNSR)
07:06 PM Red Hat Jumps on Q1 Results (RHT)
07:05 PM Micron Reports Q3 Results Ahead of Estimates (MU)
07:03 PM Jabil Circuit Posts Lower Q3 Profit (JBL)
06:17 PM Benzinga's M&A Chatter for Wednesday June 19, 2013
5:40 PM Red Hat, Inc. Sees Q2 EPS $0.32-0.33 vs $0.33 Est; Sees Sales $370.0M-373.0M vs $373.20M Est
5:31 PM S&P Lowers Outlook on DISH to Negative
5:24 PM Form 8-K Filing from Depomed Shows FDA Web Site Indicates ANDA for Generic Zipsor Submitted, Says Zipsor Protected by Five Patents
5:22 PM Fulton Financial Files Mixed Securities Shelf
5:16 PM Whitestone REIT May Offer Up to $50M Shares

stats for benzinga